Last updated: September 17, 2026
Claritin Hives Relief RediTabs is an over-the-counter loratadine 10 mg orally disintegrating tablet marketed by Bayer in the United States. The product treats allergy symptoms and hives-related itching without the prescription restrictions that applied to loratadine before its 2002 OTC switch. Its commercial position is mature rather than growth-oriented: generic loratadine, store brands, competing antihistamines, and private-label substitution limit pricing power.
Bayer does not publicly report revenue, profit, or volume for Claritin Hives Relief RediTabs as a standalone SKU. Financial performance must therefore be assessed through Bayer’s Consumer Health segment, the broader U.S. allergy market, Claritin brand activity, and the economics of mature OTC products. The product has no meaningful remaining small-molecule exclusivity barrier, and its principal defenses are brand recognition, retail placement, formulation convenience, packaging, and consumer loyalty.
What is Claritin Hives Relief RediTabs?
Claritin Hives Relief RediTabs contains loratadine, a second-generation antihistamine. The RediTabs format is designed to dissolve on the tongue without water.
| Attribute |
Product profile |
| Brand |
Claritin |
| Product |
Claritin Hives Relief RediTabs |
| Active ingredient |
Loratadine |
| Strength |
10 mg per tablet |
| Dosage form |
Orally disintegrating tablet |
| Regulatory status |
OTC drug |
| Primary uses |
Temporary relief of allergy symptoms and hives-related itching |
| U.S. marketer |
Bayer HealthCare LLC |
| Prescription status |
No prescription required |
| Market category |
Allergy and antihistamine OTC |
| Primary competitors |
Zyrtec, Allegra, generic loratadine, store-brand antihistamines |
The product’s value proposition is convenience rather than pharmacological differentiation. Loratadine is widely available in conventional tablets, softgels, liquids, chewables, and orally disintegrating formats.
When did Claritin lose prescription exclusivity and OTC market protection?
Claritin’s prescription-to-OTC transition occurred in 2002. FDA approved the switch of loratadine from prescription status to nonprescription status after the agency determined that consumers could use the medicine safely and effectively without professional supervision (U.S. Food and Drug Administration [FDA], 2002).
The commercial timeline is:
| Period |
Event |
Commercial impact |
| 1990s |
Loratadine sold as a prescription antihistamine |
High branded pricing and prescription-channel economics |
| 2002 |
FDA approves OTC switch |
Large increase in consumer access and market volume |
| Early 2000s |
Generic loratadine and retailer brands expand |
Rapid price competition |
| 2010s |
Mature OTC category develops |
Growth shifts to brand management and channel execution |
| 2020s |
RediTabs competes in a crowded format market |
Convenience and shelf visibility become central |
The original loratadine patent estate expired long before the current commercial period. Claritin RediTabs is therefore not protected by a live primary-compound monopoly. Its market position depends on commercial assets rather than patent exclusivity.
What is the FDA regulatory status of Claritin Hives Relief RediTabs?
Claritin Hives Relief RediTabs is regulated as an OTC drug. Its labeling is governed by FDA requirements for antihistamine products and the applicable OTC monograph framework. The product is sold with Drug Facts labeling that identifies loratadine as the active ingredient and provides dosing, warnings, and use information.
The FDA-approved OTC transition materially changed the product’s economic model. The business moved from physician-directed prescription demand to consumer self-selection, retailer promotion, seasonal merchandising, and direct price comparison.
Unlike a prescription product, the current commercial analysis does not center on abbreviated new drug application litigation or Orange Book patent certifications.
What is the Orange Book status of Claritin Hives Relief RediTabs?
Claritin Hives Relief RediTabs is not an ordinary current Orange Book exclusivity case. Orange Book litigation and Paragraph IV certifications principally apply to approved prescription drugs and certain approved drug products subject to listing requirements. An OTC loratadine product marketed under the monograph system does not have the same Orange Book-based exclusivity structure as a patented prescription medicine.
Key consequences include:
- No meaningful current Orange Book barrier prevents generic loratadine competition.
- Generic manufacturers do not need to wait for a Claritin-specific patent term to expire.
- A competitor can enter with loratadine in an equivalent OTC dosage form if it complies with FDA requirements.
- Brand protection depends heavily on trademarks, packaging, distribution, and consumer demand.
What patents protect Claritin Hives Relief RediTabs?
The commercially relevant loratadine compound patents have expired. Any early Claritin patent estate cannot prevent current generic loratadine competition.
Potential IP categories associated with the product include:
| IP category |
Current commercial relevance |
| Original loratadine compound patents |
Expired |
| Early prescription formulation patents |
Expired or commercially ineffective against ordinary generic loratadine |
| RediTabs formulation claims |
Potentially relevant only if a live, enforceable claim covers a specific implementation |
| Manufacturing methods |
May protect a process but generally do not prevent alternative loratadine manufacture |
| Trademarks |
Important for Claritin brand positioning |
| Packaging and trade dress |
Useful for shelf differentiation, subject to competition-law and trademark limits |
| Labeling and consumer claims |
Supports marketing but does not create drug exclusivity |
Public commercial information does not establish a current patent block that prevents competing loratadine orally disintegrating tablets. The product’s formulation may have historically been supported by formulation and delivery-system patents, but those rights do not restore compound-level exclusivity.
How strong is the patent estate for Claritin Hives Relief RediTabs?
The patent estate is weak as a barrier to generic entry and stronger as a historical record of formulation innovation.
A practical assessment is:
| Patent-strength factor |
Assessment |
| Active ingredient protection |
None of practical importance |
| Formulation protection |
Limited and potentially claim-specific |
| Manufacturing protection |
Possible process differentiation, but substitutes may exist |
| Method-of-use protection |
Minimal for broad OTC allergy and hives indications |
| Orange Book leverage |
Limited |
| Paragraph IV exposure |
Low strategic relevance for an OTC monograph product |
| Brand and trademark protection |
Material |
| Retail and distribution strength |
Material |
| Overall barrier to entry |
Low |
The RediTabs format may provide a modest product-level advantage because some consumers prefer a tablet that dissolves without water. That advantage is easier to copy than a novel active ingredient and is vulnerable to store-brand equivalents.
What generic entry risks exist for Claritin Hives Relief RediTabs?
Generic entry risk is already realized rather than prospective. Loratadine is sold by numerous generic manufacturers and retailers, including products in tablet, chewable, liquid, and orally disintegrating formats.
The main substitution risks are:
- Generic loratadine tablets priced below Claritin.
- Store-brand orally disintegrating loratadine.
- Alternative non-drowsy antihistamines such as cetirizine and fexofenadine.
- Retailer promotion that directs consumers toward private-label products.
- E-commerce search results that make ingredient-level price comparison immediate.
- Multi-symptom allergy products that bundle antihistamines with decongestants or other ingredients.
The commercial question is not whether generic entry can occur. It is how much of the remaining branded consumer demand Bayer can retain despite broad ingredient substitution.
How does Claritin RediTabs compare with Zyrtec and Allegra?
Claritin competes in the non-drowsy antihistamine segment with Johnson & Johnson’s Zyrtec, Haleon’s Allegra, and retailer-owned equivalents.
| Product family |
Active ingredient |
Commercial positioning |
Main risk to Claritin |
| Claritin |
Loratadine |
Non-drowsy allergy relief; broad brand awareness |
Generic and private-label substitution |
| Zyrtec |
Cetirizine |
Strong allergy-relief positioning |
Consumer preference for perceived potency |
| Allegra |
Fexofenadine |
Non-drowsy, long-lasting relief |
Brand switching and seasonal promotion |
| Generic loratadine |
Loratadine |
Low-price ingredient equivalent |
Direct price erosion |
| Store-brand ODT loratadine |
Loratadine |
Convenience at lower price |
RediTabs format substitution |
Loratadine has a long consumer history and broad availability. Cetirizine is often perceived by consumers as stronger but may be associated with more drowsiness in some users. Fexofenadine is positioned around non-drowsiness and duration. Product choice is shaped by perceived efficacy, prior experience, price, package size, and retailer placement.
What are the market dynamics for Claritin Hives Relief RediTabs?
The product operates in a mature, highly competitive OTC market. Demand is seasonal but not limited to pollen season because consumers also use antihistamines for perennial allergies and hives.
Seasonality
Sales generally rise during:
- Spring tree-pollen season.
- Summer grass and outdoor exposure periods.
- Late summer and fall weed-pollen season.
- Retail promotional windows before peak allergy periods.
Hives-related use provides a second demand pathway, but the product is not a dedicated prescription urticaria therapy. Consumers with persistent or severe hives may move to physician-directed treatment, including newer prescription antihistamine regimens or biologic therapy.
Pricing
Claritin RediTabs is exposed to a broad price ladder:
- Premium branded RediTabs.
- Standard branded Claritin tablets.
- Authorized or retailer-branded loratadine.
- Low-priced generic tablets.
- Larger value packs sold through mass retailers and online channels.
The orally disintegrating format can support a price premium, but the premium is constrained when consumers recognize that the active ingredient is loratadine and equivalent lower-priced formats are available.
Distribution
The principal channels are:
- Mass merchandisers.
- Pharmacies.
- Grocery stores.
- Club stores.
- E-commerce marketplaces.
- Direct-to-consumer brand websites.
Retailer bargaining power is high. Shelf position, seasonal circulars, digital search placement, and value-pack architecture can have a greater effect on sales than incremental formulation changes.
What is the financial trajectory of Claritin Hives Relief RediTabs?
No public filing provides standalone revenue or operating profit for Claritin Hives Relief RediTabs. Bayer reports Consumer Health results at the segment and category level rather than at the individual SKU level. The product’s financial trajectory can therefore be divided into four phases.
| Phase |
Financial pattern |
Main driver |
| Prescription period |
High unit economics and physician-directed demand |
Prescription brand and patent protection |
| OTC switch |
Rapid volume expansion with lower per-unit pricing |
Consumer access and mass retail |
| Generic erosion |
Declining branded share and price pressure |
Loratadine substitution |
| Mature OTC period |
Stable or fluctuating sales with promotional dependence |
Seasonality, brand equity, and distribution |
Bayer’s Consumer Health division includes allergy products alongside analgesics, nutritional supplements, dermatology products, and other self-care categories. Segment results provide context but do not isolate Claritin RediTabs. Bayer has reported Consumer Health sales in the multibillion-euro range, reflecting the scale of the overall portfolio rather than the value of this individual product (Bayer AG, 2024).
The likely economic profile of RediTabs is:
- Low regulatory development cost relative to prescription products.
- Low probability of major price expansion.
- Moderate gross-margin potential for branded units.
- High promotional sensitivity.
- Limited capital intensity.
- Ongoing margin pressure from retailer brands.
- Value concentrated in brand recognition and distribution.
The product can remain profitable without holding pharmaceutical exclusivity because OTC brands generate revenue from repeat purchase, shelf presence, and consumer trust. Its financial trajectory is more likely to be gradual erosion or stabilization than high growth.
Does Claritin Hives Relief RediTabs have biosimilar risk?
No. Biosimilar risk does not apply because loratadine is a chemically synthesized small molecule, not a biologic. The relevant competitive threats are generic drugs, private-label OTC products, and alternative antihistamines.
This distinction matters for valuation. A biologic faces biosimilar entry through a regulatory pathway tied to the reference product. Claritin faces ordinary ingredient substitution and retail competition, which usually produces faster and more extensive price erosion.
Which companies are challenging Claritin in the market?
The competitive field includes generic manufacturers, retailers, and branded OTC companies.
Branded competitors
- Johnson & Johnson or its consumer-health successors through Zyrtec-related products.
- Haleon through Allegra.
- Other regional and national OTC companies.
Generic and private-label competitors
- Perrigo.
- Viatris.
- Teva.
- CVS, Walgreens, Walmart, Target, and other retailer brands.
- Contract manufacturers supplying private-label loratadine.
The most direct challenge comes from store-brand loratadine in equivalent strengths and dosage forms. Retailers can capture margin by replacing national-brand units with private-label products while preserving the same active ingredient and consumer use case.
What licensing deals affect Claritin Hives Relief RediTabs?
No current, product-specific licensing arrangement for Claritin Hives Relief RediTabs is broadly disclosed in Bayer’s public financial reporting. Claritin’s current economics are primarily controlled through Bayer’s consumer-health organization and retail distribution relationships.
Historically, Claritin was associated with Schering-Plough before Bayer acquired Merck’s consumer-care business in 2014. The transaction transferred a broad consumer-health portfolio, including established brands, rather than creating a new exclusivity position for loratadine (Bayer AG, 2014).
What patent litigation or settlement agreements affect Claritin?
No active, product-defining patent litigation or settlement agreement is central to the current commercial status of Claritin Hives Relief RediTabs. The significant legal transition occurred earlier, when loratadine moved from a prescription product into a competitive OTC market.
The present legal risk profile focuses on:
- Trademark enforcement.
- Advertising substantiation.
- Packaging and trade dress.
- OTC labeling compliance.
- Retailer and distributor contracts.
- Product liability and quality controls.
Paragraph IV settlements are not the principal mechanism governing competitive entry for this OTC product.
What generic launch scenarios could affect Claritin sales?
Scenario 1: Continued branded erosion
Consumers increasingly purchase low-priced loratadine equivalents, while Claritin retains a premium position among brand-loyal users. Revenue declines gradually, with seasonal promotions supporting volume.
Scenario 2: RediTabs-specific private-label expansion
Retailers expand orally disintegrating loratadine offerings. This scenario would pressure the product more directly because it removes the convenience-based distinction between Claritin RediTabs and standard generic tablets.
Scenario 3: Stable brand niche
Claritin retains demand from consumers who prefer the brand or specifically seek a no-water dosage form. Bayer preserves distribution and package visibility, but growth remains limited.
Scenario 4: Category share shift to competing antihistamines
Zyrtec or Allegra gains share through efficacy perceptions, advertising, or retailer promotion. Claritin sales decline even if total allergy-category demand remains stable.
What geographic coverage does Claritin have?
Claritin is an international brand, but product names, dosage forms, marketers, claims, and regulatory status vary by country. The U.S. RediTabs product is an OTC loratadine product sold through American retail and e-commerce channels.
Geographic commercial differences include:
- Different OTC monographs and labeling rules.
- Different patent and trademark histories.
- Different retailer structures.
- Variable availability of generic loratadine.
- Different consumer preferences for tablets, liquids, sprays, or combination products.
- Country-specific ownership or licensing arrangements.
U.S. revenue cannot be extrapolated directly to global Claritin performance.
Key Takeaways
- Claritin Hives Relief RediTabs is a mature OTC loratadine 10 mg orally disintegrating tablet.
- Bayer does not publicly disclose standalone revenue or profit for the product.
- The original loratadine patent estate has expired, and generic entry is already established.
- Orange Book and Paragraph IV mechanisms have limited relevance to the current OTC business.
- The main competitive threats are generic loratadine, private-label RediTabs equivalents, Zyrtec, and Allegra.
- The product’s defensible assets are brand recognition, retail distribution, packaging, and convenience.
- Financial performance is likely characterized by stable-to-declining branded demand, seasonal volume, promotional pressure, and limited pricing power.
- Biosimilar risk does not apply.
- Formulation and manufacturing IP may provide narrow protection but does not create a meaningful market-entry barrier.
- Future value depends more on Bayer’s consumer-health execution than on pharmaceutical exclusivity.
FAQs
Is Claritin Hives Relief RediTabs the same as regular Claritin?
It contains the same active ingredient, loratadine, at 10 mg per tablet. The principal difference is the orally disintegrating RediTabs dosage form.
Can generic loratadine replace Claritin RediTabs?
Yes. Generic loratadine can provide an equivalent active ingredient, although dosage form, excipients, packaging, and consumer experience may differ.
Does Claritin RediTabs require a prescription?
No. The product is sold over the counter in the United States.
Is Claritin RediTabs protected by a current U.S. drug patent?
There is no publicly evident active compound-level patent barrier preventing competing loratadine products. Any remaining formulation rights would be narrow and implementation-specific.
Is Claritin Hives Relief RediTabs a high-growth pharmaceutical product?
No. It is a mature OTC product in a competitive antihistamine market. Its commercial outlook depends on brand retention, retail placement, seasonal demand, and management of generic substitution.
References
-
Bayer AG. (2014). Bayer to acquire Merck’s consumer care business. Bayer.
-
Bayer AG. (2024). Annual report 2023. Bayer.
-
U.S. Food and Drug Administration. (2002). FDA approves Claritin, Allegra, and Zyrtec for over-the-counter use. FDA.
-
U.S. Food and Drug Administration. (2024). Drug facts label: Claritin RediTabs loratadine orally disintegrating tablets. FDA.
-
U.S. Food and Drug Administration. (2024). OTC monograph M012: Antihistamine drug products for over-the-counter human use. FDA.
